Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study  by Phyo, Aung Pyae et al.
Articles
1960 www.thelancet.com   Vol 379   May 26, 2012
Lancet 2012; 379: 1960–66
Published Online
April 5, 2012
DOI:10.1016/S0140-
6736(12)60484-X
See Comment page 1928
Faculty of Tropical Medicine, 
Mahidol University, Bangkok, 
Thailand (A P Phyo MD, 
K Stepniewska PhD, 
E A Ashley MD, R McGready MD, 
A M Dondorp MD, 
P Singhasivanon MD, 
N P J Day FRCP, N J White FRS, 
F Nosten MD); Shoklo Malaria 
Research Unit, Mae Sot, Tak, 
Thailand (A P Phyo, E A Ashley, 
R McGready, C Ier Moo, 
K Maung Lwin MD, F Nosten); 
Texas Biomedical Research 
Institute, San Antonio, Texas, 
USA (S Nkhoma PhD, S Nair MSc, 
S Al-Saai MSc, 
T J C Anderson PhD); Centre for 
Tropical Medicine, Churchill 
Hospital, Oxford, UK 
(K Stepniewska, E A Ashley, 
R McGready, A M Dondorp, 
N P J Day, N J White, F Nosten); 
and Worldwide Antimalarial 
Resistance Network, Oxford, 
UK (K Stepniewska)
Correspondence to:
Prof François Nosten, 
Shoklo Malaria Research Unit, 
PO Box 46, Mae Sot, Tak, 
Thailand 63110
francois@tropmedres.ac
Emergence of artemisinin-resistant malaria on the western 
border of Thailand: a longitudinal study
Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniewska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, 
Arjen M Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White, Tim J C Anderson, François Nosten
Summary
Background Artemisinin-resistant falciparum malaria has arisen in western Cambodia. A concerted international eﬀ ort 
is underway to contain artemisinin-resistant Plasmodium falciparum, but containment strategies are dependent on 
whether resistance has emerged elsewhere. We aimed to establish whether artemisinin resistance has spread or emerged 
on the Thailand–Myanmar (Burma) border.
Methods In malaria clinics located along the northwestern border of Thailand, we measured six hourly parasite counts in 
patients with uncomplicated hyperparasitaemic falciparum malaria (≥4% infected red blood cells) who had been given 
various oral artesunate-containing regimens since 2001. Parasite clearance half-lives were estimated and parasites were 
genotyped for 93 single nucleotide polymorphisms.
Findings 3202 patients were studied between 2001 and 2010. Parasite clearance half-lives lengthened from a geometric 
mean of 2·6 h (95% CI 2·5–2·7) in 2001, to 3·7 h (3·6–3·8) in 2010, compared with a mean of 5·5 h (5·2–5·9) in 
119 patients in western Cambodia measured between 2007 and 2010. The proportion of slow-clearing infections (half-life 
≥6·2 h) increased from 0·6% in 2001, to 20% in 2010, compared with 42% in western Cambodia between 2007 and 2010. 
Of 1583 infections genotyped, 148 multilocus parasite genotypes were identiﬁ ed, each of which infected between two and 
13 patients. The proportion of variation in parasite clearance attributable to parasite genetics increased from 30% between 
2001 and 2004, to 66% between 2007 and 2010.
Interpretation Genetically determined artemisinin resistance in P falciparum emerged along the Thailand–Myanmar 
border at least 8 years ago and has since increased substantially. At this rate of increase, resistance will reach rates 
reported in western Cambodia in 2–6 years.
Funding The Wellcome Trust and National Institutes of Health.
Introduction
Artemisinin combination treatments are the recom-
mended ﬁ rst-line therapy for falciparum malaria. 
Plasmodium falciparum parasites with reduced in-vivo 
susceptibility to artemisinin derivatives (eg, artesunate) 
have emerged in western Cambodia.1–3 This ﬁ nding 
threatens worldwide initiatives to control and eliminate 
malaria.4 Resistance to the previous mainstays of anti-
malarial treatment—namely, chloroquine and sulfadoxine–
pyrimethamine—also arose in western Cambodia5–7 and 
spread across southeast Asia into Africa, resulting in the 
deaths of millions of children.8,9 If resistance to artemisinin 
is conﬁ ned to the Cambodia–Thailand border, regional 
elimination of falciparum malaria will probably be 
necessary for containment.10,11 However, if resistant para-
sites have already spread or emerged elsewhere, then the 
containment zone will need to be extended and the strategy 
reconsidered.3,7
Artemisinin resistance is characterised by slow parasite 
clearance.1,2,12 Clearance (assessed by microscopy) of 
sensitive P falciparum is achieved within 2 days in 95% of 
patients,13 whereas artemisinin-resistant infections remain 
slide-positive for 3 or more days; treatment failure is more 
common in such infections after arte misinin combination 
treatment. High-grade artemisinin resistance has not been 
reported. Laboratory studies and mathematical modelling 
suggest that slow clearance of resistant parasites mainly 
results from decreased susceptibility of ring-stage parasites 
to artemisinin and its derivatives.14 No laboratory assays 
reliably identify artemisinin-resistant parasites.2 Patients 
from western Cambodia with similar parasite clearance 
rates are infected with genetically in dis tin guishable 
parasite clones, suggesting that parasite genetics have a 
central role in determination of this trait,15 although the 
genes responsible are unknown.
On the northwestern border of Thailand, 800 km 
from western Cambodia, treatment failure rates with 
artesunate and meﬂ oquine combinations have increased.16 
In this area, patients without signs of severity but with 
more than 4% parasitaemia (ie, parasites present in 4% or 
more of red blood cells) are given oral artesunate regimens, 
which have proven superior to intravenous quinine.17,18 
High admission parasitaemias allow for accurate assess-
ment of parasite clearance rates. To assess whether 
artemisinin resistance has emerged in this strategically 
important area, we analysed over 10 years the longitudinal 
changes in parasite clearance rates in a large prospective 
series of hyperparasitaemic patients given artesunate. 
Parasites were genotyped to establish the contribution of 
parasite genetics to parasite clearance rates.
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Methods
Study site and patients
Data were obtained from patients with a high parasite 
count (>4% infected red blood cells) but no signs of severe 
malaria routinely admitted to malaria clinics run by the 
Shoklo Malaria Research Unit, which span a 150 km 
region of the northwestern border of Thailand. Maela 
(refugee camp) and Wang Pha village are north of Mae Sot 
town (where the research unit is based), whereas Mae Kon 
Khen and Mawker Thai villages are south (appendix). 
Most patients came from adjacent Myanmar (Burma). We 
compared the parasite clearance data with results from 
119 patients studied in Pailin, western Cambodia 
(2007–10), where artemisinin resistance has been 
conﬁ rmed.2 A subset of 30 parasite genotypes from Pailin 
was part of the genetic analysis. These studies were 
approved by the ethics review boards of the Faculty of 
Tropical Medicine, Mahidol University. 
Falciparum malaria was diagnosed by microscopy of 
thick and thin peripheral blood smears stained with 
Giemsa. Parasite counts were read per 1000 red cells (thin 
ﬁ lm) or 500 white cells (thick ﬁ lm). Uncomplicated 
hyper parasitaemia was deﬁ ned as 4% or more of red cells 
infected with malaria parasites without clinical evidence 
of severe malaria,19 and was the only criterion for inclusion 
in the analysis. Routine care was hospitalisation with a six 
hourly blood smear to monitor parasite clearance until 
smears were slide-negative. Treatment was with a 7 day 
regimen of oral artesunate (4 mg/kg initially, then 
2 mg/kg once daily for 7 days), usually combined with 
either meﬂ oquine (25 mg/kg in two divided doses), or 
doxycycline (4 mg/kg per day for 7 days) or clindamycin (5 
mg/kg three times daily for 7 days) if meﬂ oquine 
was contraindicated. In cases of clinical deterioration 
parenteral treatment was substituted. We monitored 
treatment until smears became slide-negative.
Procedures
DNA was extracted from admission blood spots by use of 
a two-step protocol to maximise DNA yield. Blood was 
eluted from six 3 mm diameter punches with the 
GenSolve kit (GenVault Corporation, Pleasanton, CA, 
USA), and DNA was then extracted with QIAamp 96 DNA 
blood kits (Qiagen, Valencia, CA, USA). Genotyping of 
96 single nucleotide poly morphisms distributed across 
the P falciparum genome was done with the Illumina 
Goldengate platform (Illumina Inc, San Diego, CA, USA) 
(appendix). We judged samples to be multiple-clone 
infections if more than ﬁ ve single nucleotide poly-
morphisms showed heterozygous base calls.
We measured the heritability of parasite clearance half-
life to assess the part that parasite genetics plays in 
determination of this trait. Multilocus parasite genotypes 
infecting two or more patients were identiﬁ ed. Such 
parasite genotypes are equivalent to identical twins reared 
apart and can be used to measure heritability of parasite 
clearance (panel 1).
The geometric mean parasite clearance half-life in 
patients with artemisinin-resistant falciparum malaria in 
western Cambodia was 6·2 h (n=36, 95% CI 5·7–6·6),2,15 
corresponding to a loge normalised distri bution with a 
mean of 1·8 (SD 0·22). Hyperparasitaemic patients on the 
northwestern border of Thailand in 2001 were used as a 
N Geometric mean parasite 
clearance half-life (95% CI)
Range % change 
(95% CI)*
p value
Artesunate and 
meﬂ oquine 
treatment†
–4·3 (–7·8 to –0·7) 0·018
No 640 3·267 (3·162–3·374) 0·730–11·613
Yes 2266 3·125 (3·072–3·180) 0·588–12·545
Admission‡ 3·4 (2·8 to 4·0)‡ <0·0001
2001 156 2·628 (2·535–2·725) 1·079–7·484
2010 156 3·674 (3·561–3·791) 1·454–9·111
Days fever 9·0 (5·7 to 12·4) <0·0001
<3 days 1467 3·030 (2·966–3·095) 0·847–11·613
≥3 days 1401 3·301 (3·230–3·374) 0·588–12·545
Admission 
gametocytaemia
13·9 (8·7 to 19·4) <0·0001
No 2563 3·108 (3·058–3·158) 0·588–12·545
Yes 343 3·540 (3·387–3·700) 0·730–10·146
Admission 
haematocrit
–9·2 (–12·8 to –5·5) <0·0001
<30% 511 3·417 (3·295–3·543) 0·730–9·804
≥30% 2395 3·103 (3·051–3·155) 0·588–12·545
Sex 0·5 (–2·6 to 3·8) 0·74
Female 1083 3·145 (3·068–3·225) 0·730–11·613
Male 1823 3·162 (3·102–3·224) 0·588–12·545
History of malaria –3·8 (–6·8 to  –0·8) 0·014
No 1301 3·235 (3·162–3·310) 0·805–12·545
Yes 1511 3·111 (3·046–3·177) 0·588–11·613
Parenteral rescue 
treatment
19·7 (13·8 to 25·9) <0·0001
No 2616 3·100 (3·051–3·149) 0·588–11·613
Yes 290 3·710 (3·537–3·892) 0·906–12·545
Blood transfusion 11·8 (3·0 to 21·4) 0·008
No 2738 3·150 (3·101–3·200) 0·588–12·545
Yes 104 3·522 (3·248–3·820) 1·260–9·804
(Continues on next page)
Panel 1: Heritability
Measurement of heritability—ie, the proportion of variance in a trait that is explained by 
genetics—is widely used in human and agricultural genetics.20 This measure is especially 
useful when the loci underlying trait variation are unknown and when the genetic and 
environmental contributions to trait variation are uncertain, as in the case of parasite 
clearance rates. Heritability can be measured in Plasmodium falciparum by comparing trait 
variation in genetically indistinguishable parasites infecting diﬀ erent patients, just as 
heritability in people can be measured with identical twins. This approach uses the fact 
that such parasites are frequently recovered from several patients in southeast Asian 
countries because of low transmission and consequently high rates of inbreeding.15 When 
resistance genes spread within a parasite population, heritability increases because 
genetic determinants have a growing role in determination of trait variation.
See Online for appendix
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reference artemisinin-sensitive population, with a mean 
loge parasite clearance half-life of 0·95 (0·33). The hypo-
thesis that the changes in parasite clearance half-life in 
western Thailand resulted from emergence versus import-
ation of parasites with the same resistance pheno type 
prevalent in western Cambodia was tested.
Statistical analysis
We assessed parasite clearance using a standardised ﬁ tting 
method that separates the variable initial lag phase, during 
which parasite counts level oﬀ  or rise, from the subsequent 
log-linear decline.12 The slope of this phase was calculated 
and expressed as the parasite clearance half-life, which is 
the time taken for parasitaemia to fall by half during log-
linear decline.21 Patients with parasite clearance curves 
showing a poor ﬁ t (R²<0·8) to the log-linear model were 
excluded from the analysis.
We used Stata (version 11) to examine the association 
between parasite clearance half-life and the following co-
variates: age, sex, history of malaria, treatment regimen 
(artesunate with meﬂ oquine vs artesunate with other part-
ner drugs or artesunate alone), date of admission, dura tion 
of fever before presentation (<3 days vs ≥3 days), admission 
parasitaemia, haematocrit (<30% vs ≥30%), gameto cyt-
aemia, blood transfusion, and parenteral rescue therapy.
Univariate regression analysis of all listed covariates was 
done on log-transformed parasite clearance half-lives, 
followed by stepwise multivariate analysis (exclud ing 
parenteral rescue therapy). Variables that only signiﬁ  cantly 
improved the ﬁ nal model (likelihood ratio test p<0·05) 
were included (tables 1, 2).
To assess heritability, variance of parasite clearance was 
compared within and between clonally identical parasites 
recovered from more than two patients. Heritability (H²) 
was estimated from the mean squares terms in ANOVA.15,21 
H² was estimated for normalised parasite clearance and 
for residuals remaining after regression of clearance rates 
against patient and environmental factors. 
We examined the hypothesis that changes in parasite 
clearance resulted from importation or emergence of 
parasites with the western Cambodian phenotype. The 
clearance rate distribution of a mixture of the western 
Cambodia and western Thailand populations was 
calculated as: π × normal([log{x} – 1·8] / 0·22) + (1 – π) × 
normal([log{x} – 0·95] / 0·33), where π is the proportion of 
infections derived from the resistant population. For each 
year, we used the Kolmogorov–Smirnov test (50 tests for 
each year) to compare recorded distributions of loge 
transformed half-lives with these theoretical distributions 
(for π between 0·01 and 0·50).
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and ﬁ nal responsibility for the 
decision to submit for publication.
% change in geometric mean 
parasite clearance half-life
95% CI p value
Study centre*
Maela 5·64 4·34 to 6·95 <0·0001
Wang Pha 2·60 1·11 to 4·11 0·00059
Mae Khon Khen 1·65 –6·09 to 10·02 0·68
Mawker Thai 1·68 0·72 to 2·65 0·00062
Presence of gametocytaemia on 
admission
5·55 0·57 to 10·78 0·029
Haematocrit <30% on admission 7·33 3·10 to 11·73 0·00056
Fever ≥3 days 7·37 4·17 to 10·67 <0·0001
*Change per year estimated within each study location. 
Table 2: Admission variables associated with parasite clearance half-life of Plasmodium falciparum in 
multivariate regression analysis
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Figure 1: Parasite clearance half-life of Plasmodium falciparum on the Thailand–Myanmar border over 10 years
We plotted untransformed parasite clearance half-lives over time for all malaria infections with a good ﬁ t to a linear 
model (R²>0.8). Data from western Cambodia gathered between June, 2007, and November, 2010, are shown for 
comparison, compressed as if they had been obtained in a single year. The dotted red line shows a threshold value of 
6·2 h, used to diﬀ erentiate between fast-clearing and slow-clearing infections. The dotted blue boxes show the 
periods for which bloodspots were available. These two time windows form the basis of the genetic analysis.
N Geometric mean parasite 
clearance half-life (95% CI)
Range % change 
(95% CI)*
p value
(Continued from previous page)
Study sites
Mawkertai§ 1035 2·945 (2·872–3·020) 0·805–12·545 ·· ··
Maela 439 2·940 (2·829–3·056) 1·028–9·385 –0·2 (–4·6 to 4·6) 0·95
Mae Khon Ken 148 2·958 (2·768–3·162) 1·205–8·636 0·5 (–6·4 to 7·9) 0·9
Wang Pha 1283 3·444 (3·367–3·523) 0·588–11·613 16·9 (13·1 to 21·0) <0·0001
*% change refers to the change in parasite clearance half-life estimated from the regression model. †Patients not given 
artesunate and meﬂ oquine received either artesunate with doxycycline or clindamycin, or artesunate alone for 7 days. 
‡Day of admission was modelled as a continuous covariate; geometric mean was estimated at the start of the study 
(2001) and 10 years later (2010). Percentage changes are give for one year. §Mawkertai was used as a reference 
location for comparison with other sites.
Table 1: Eﬀ ect of covariates on parasite clearance half-life of Plasmodium falciparum examined by 
univariate analysis
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Results
Between July, 2001, and December, 2010, 3202 hyper-
parasitaemic patients were treated. Most patients were 
younger than 15 years (appendix). Most patients (2403) 
were given oral artesunate and divided doses of 
meﬂ oquine. The remaining patients were given arte-
sunate monotherapy (321 patients), artesunate in 
combination with either doxycycline (382 patients) or 
clindamycin (71 patients), or other combinations (25 pa-
tients). Patients who got blood transfusions within 
24 hours of admission, or an incom plete course of or 
more than one parenteral dose of artesunate were 
excluded from the analysis. 2855 patients (1268 in 
Wang Pha, 975 in Mawker Thai, 467 in Maela, and 
145 in Mae Khon Ken) remained eligible, of whom 
1778 (62%) were men or boys. In 1759 of 2855 patients, 
artesunate monotherapy was given, or else the partner 
drug (meﬂ oquine, doxycycline, or clindamycin) was 
given more than 48 h from the start of artesunate 
treatment. All patients survived, conﬁ rming the 
eﬀ ectiveness of oral artesunate in uncomplicated 
hyperparasitaemia.18
Between 2001 and 2010, the median age of hyper-
parasitaemic patients increased slightly but signiﬁ cantly 
from 11 years to 15 years (p<0·0001). The proportion of 
patients developing severe malaria did not increase over 
time, nor did the ratio of severe to uncomplicated falci-
parum malaria cases, malaria mortality, nor the proportion 
of patients developing anaemia. We noted a signiﬁ cant 
increase in the proportion of patients with gametocytaemia 
on admission (p<0·0001; 7·5×10–⁶ test for trend).
Parasite clearance half-life lengthened from a geometric 
mean of 2·6 h (95% CI 2·5–2·7) in 2001, to 3·7 h (3·6–3·8) 
in 2010 (p<0·0001), compared with 5·5 h (5·2–5·9) in the 
116 patients from western Cambodia between 2007 and 
2010 (clearance data from three patients ﬁ tted poorly to the 
linear model [R²<0·8] and were thus excluded) (ﬁ gures 1, 
2A, table 1). We used a stringent threshold of a parasite 
clearance half-life of more than 6·2 h to cate gorise 
infections with slow or fast parasite clearance; the 
proportion of patients at our study centres with slow 
clearance rose from 0·6% in 2001, to 20% in 2010, 
compared with 42% of patients in western Cambodia in 
2010 (ﬁ gure 2B). Parasite clearance rates in patients given 
artesunate monotherapy or given artesunate alone for 
more than 48 h (n=1759) before receiving partner drugs 
were similar to those in patients who were given 
combination treatments immediately, suggesting that 
increasing resistance to the partner drug cannot explain 
the temporal changes reported.
No relation existed between parasite clearance half-life 
and age (p=0·439) or starting parasitaemia (p=0·598) in 
patients given artesunate monotherapy or given artesunate 
alone for more than 48 h before receiving partner drugs, 
nor in all patients (p=0·124 and p=0·569, respectively). 
The variable most strongly associated with increases in 
parasite clearance half-life was the date of patient 
admission (appendix). This trend was strongly signiﬁ cant 
in all clinics sampled except Mae Khon Ken, Thailand 
(table 2; appendix). Only 7·4% of the variation in half-life 
could be explained by other admission variables. Location 
had a signiﬁ cant eﬀ ect on parasite clearance; infections in 
northern locations (ie, Maela and Wang Pha) had slower 
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Figure 2: Change in parasite clearance half-life of Plasmodium falciparum 2001–10 
(A) Geometric means of parasite clearance half-life in patients with hyperparasitaemia on the Thailand–Myanmar 
border. *Subset of infections treated with artesunate monotherapy (ART) for more than 48 h, for which 48 h 
clearance rates and parasite clearance half-lives were calculated. Error bars are 95% CIs and above them is the 
number of patients. (B) Proportion of patients with very slow clearance (parasite clearance half-life≥6·2 h). Error 
bars are binomial 95% CIs. Colour scheme is as per A.
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clearance than those sampled in the south (ie, Mawker Thai 
and Mae Khon Ken) (appendix; table 2).
Of 96 single nucleotide polymorphisms assessed, 
93 gave robust genotype data. Of the 1583 infections 
genotyped, 1029 were single-clone infections (appendix). 
From these, 148 unique 93-locus parasite genotypes were 
identiﬁ ed, each infecting between two and 13 patients 
(29 from 2001 to 2004, and 119 from 2007 to 2010) 
(appendix). Patients harbouring parasites with the same 
93-locus genotype had similar parasite clearance half-
lives (ﬁ gure 3), showing the important part played by 
parasite genotype. Between 2001 and 2004, parasite 
genotype had a signiﬁ cant eﬀ ect on parasite clearance 
half-life (p=0·0166), even after adjusting for signiﬁ cant 
covariates (p=0·01). Two of the three patients with the 
longest parasite clearance half-lives recorded before 
2004 had the same 93-locus genotype (ﬁ gure 3). From 
2007 to 2010, parasite genotype had a much stronger 
eﬀ ect on parasite clearance half-life (p<0·0001) than it 
had between 2001 and 2004, and remained highly 
signiﬁ cant after adjusting for other covariates (F=5·219, 
df=118, p<0·0001). Mean H² increased from 
0·30 (SD 0·14) in 2001–04, to 0·66 (0·04) in 2007–10. 
After adjustment for the eﬀ ects of covariates, H² rose 
from 0·32 (0·14) between 2001–04, to 0·58 (0·05) in 
2007–10 (appendix). The increase in H² was tested by 
permutation and was signiﬁ cant both before (p<0·01) 
and after (p=0·04) adjustment for covariates (appendix).
To investigate whether the increase in H² was driven by 
alleles conferring slow parasite clearance, we removed 
30% of the slowest clearing infections from the 
2007–10 dataset, which caused H² to decrease from 
0·66 (SD 0·04) to 0·17 (0·07). Removal of 30% of the 
fastest clearing infections increased H² to 0·70 (0·05), 
whereas random removal of 30% of infections did not 
alter H² (mean H² from 100 randomisations 0·67 (0·03); 
range 0·56–0·74). These in-silico experiments show that 
high H² is driven by parasite genes that determine slow 
parasite clearance.
Admixture of parasites with the Cambodian phenotype 
could explain the parasite clearance distributions in 
2001–02, and 2009–10, but not those between 2003 and 
2008 (p<0·01). This ﬁ nding suggests that the gradual 
increases in parasite clearance half-life are unlikely to be 
explained by a single-step process of importation or de-
novo selection of a parasite population with the same 
characteristics as the resistant parasites prevalent in 
western Cambodia.
None of the 93-locus genotypes was common to patients 
from the Thailand–Myanmar border and western 
Cambodia. Pairwise allele sharing (ps) between the 
25 slowest and 25 fastest clearing parasites from the 
Thailand–Myanmar border was compared with 30 slow-
clearing parasites from western Cambodia. Cambodian 
parasites were more closely related (ps=0·453) to slow-
clearing parasites than to fast-clearing parasites (ps=0·450) 
from the Thailand–Myanmar border. However, permu-
tation tests show that this diﬀ erence is not signiﬁ cant 
(p=0·137, 10 000 permutations).
Discussion
This large prospective series of patients with hyper-
parasitaemia during 10 years provides clear evidence that 
parasite clearance responses after artesunate treatment are 
slowing on the northwestern border of Thailand (panel 2). 
The rate of decline is consistent with theoretical 
expectations and empirical data for the spread of resistance 
loci through a parasite population under drug selection.27–29 
If the rate of decline continues then parasite clearance half-
lives on the Thailand–Myanmar border will be similar to 
those in western Cambodia within 2–6 years.
Parasite clearance after treatment with artemisinin 
derivatives is determined mainly by drug eﬀ ectiveness, 
although host immunity and the partner drug can also 
contribute.12 The frequency of malaria and the proportion 
of multiple-clone infections (appendix) in the study area in 
northwestern Thailand have fallen over the past 10 years; 
thus immunity to malaria has probably also declined. 
Because patients with hyperparasitaemia are unable to 
control their infection, changes in immunity are unlikely 
to have contributed substantially to the slowing of parasite 
clearance. The absence of any relation with age in this 
study provides strong support for this contention.
Similarly, although previous malaria exposure has a 
weak eﬀ ect on parasite clearance half-life (table 1), this 
ﬁ nding cannot explain the temporal trends noted (appen-
dix). The artemisinin combination treatment partner drug 
meﬂ oquine has been used in this region for more than 
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Figure 3: Eﬀ ect of parasite genotype on parasite clearance rates
Clearance half-lives in patients infected with parasites bearing identical 93-locus genotypes. Red dotted line marks 
the 6·2 h threshold used to categorise slow-clearing parasites. The arrows show slow clearance parasite genotypes 
gathered in November, 2003. *Ranked by mean parasite clearance half-life.
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25 years, and resistance developed rapidly after initial 
deploy ment. The proportion of P falciparum isolates with 
increased pfmdr1 copy numbers (the main determinant of 
meﬂ oquine resistance) has been increasing over the past 
decade.16 However, the temporal changes in parasite 
clearance half-lives for patients given artesunate mono-
therapy for more than 48 h before administration of part-
ner drugs were closely related to those reported in the full 
dataset, showing that resistance to the partner drug does 
not contribute substantially to the changes recorded 
(ﬁ gure 2).
The genotyping data provide compelling evidence that 
parasite genetic factors explain the fall in parasite clear-
ance rates. In this low transmission setting, diﬀ erent 
patients are often infected with genetically very similar 
parasites, allowing assessment of the contribution of 
genetic factors to in-vivo phenotypes.15,30 After adjustment 
for covariates, the heritability of parasite clearance 
increased during the study period, from 32% between 
2001 and 2004, to 58% between 2007 and 2010, which is 
consistent with an increasing prevalence of alleles 
determining slow parasite clearance.20 The increased 
contribution of genetics was conﬁ ned largely to the 
parasites with the slowest clearance rates. The high 
heritability of slow parasite clearance suggests that this 
trait will spread rapidly under continued selection.
This study shows the importance of longitudinal 
detailed monitoring to detect the early emergence of 
antimalarial drug resistance. Hyperparasitaemic patients 
provide important information on temporal trends in 
artemisinin susceptibility because confounding by 
immunity and partner drug eﬀ ects is minimised and 
clearance rates can be assessed accurately (>10 sequential 
parasite counts for individual patients in this analysis). 
The slope, and thus the derived parasite clearance 
half-life of the exponential decline (ignoring the variable 
lag phase) is judged the key pharmacodynamic deter-
minant of the artemisinins.21 No evidence suggests 
saturation or density dependence in parasite clearance 
rates. Thus parasite clearances in patients with 
hyperparasitaemia can be compared with data from 
patients with lower parasitaemias, notably the artemisinin-
resistant P falciparum infections in western Cambodia.
This study cannot establish whether resistance alleles 
present in western Cambodia and northwestern Thailand 
have a common origin. Parasites with identical 93-locus 
genotypes were not recorded at the two sites, nor were 
slow clearing parasites from northwestern Thailand more 
closely related to Cambodian parasites than were fast 
clearing parasites from western Thailand. The evolution of 
artemisinin resistance will possibly be understood when 
the genetic determinants of parasite clearance rates have 
been identiﬁ ed.7,31
Parasite clearance rates in northwestern Thailand are 
continuously distributed. Modelling of the changes in 
parasite clearance over time did not support selection of a 
single artemisinin-resistant subpopulation with the same 
clearance phenotype as in Cambodia—ie, a one-step pro-
cess. Together with the ﬁ nding that clonally identical para-
sites with slow parasite clearance were reported in diﬀ erent 
patients in northwestern Thailand 8 years ago, this result 
argues against recent importation of Cambodian parasites 
as the explanation for the reduction in parasite clearance.
The artesunate–meﬂ oquine combination has been the 
ﬁ rst-line treatment for falciparum malaria on the western 
border of Thailand since 1994. Artesunate was added to a 
failing meﬂ oquine regimen, and the high eﬀ ectiveness of 
the combination (>90% day 42 cure rates) has been 
sustained since then, although evidence suggests that 
eﬀ ectiveness is decreasing,16 with a day 42 cure rate in 
86 patients in 2010 of 88·9% (95% CI 77·8–94·7). Declining 
artemisinin eﬀ ective ness will have an adverse eﬀ ect on the 
treatment of uncomplicated falciparum malaria by slowing 
therapeutic responses and increasing treatment failure 
rates, and will reduce the remarkable life-saving eﬀ ective-
ness of artesunate in the treatment of severe malaria and 
hyperparasitaemic patients. The degree to which current 
rates of resistance compromise these beneﬁ ts has not been 
established, although the proportion of patients developing 
severe malaria did not increase concomitantly with the 
decline in artesunate eﬀ ectiveness in this location. No 
patient died in this series, whereas in the past the mortality 
rate in patients given quinine for uncomplicated hyper-
parasitaemia was 3%.
A potential radical approach to containment of artemi-
sinin resistance is to try to eliminate P falciparum malaria 
from western Cambodia, but would this strategy be 
justiﬁ ed if resistance has already spread or emerged 
Panel 2: Research in context
Systematic review
We searched for trials on artemisinin resistance on PubMed using the term “resistance” in 
combination with “artemisinin”, “artesunate”, or “artemether”, and conﬁ ned the search to 
clinical studies in which resistance had been suspected or conﬁ rmed on the basis of 
assessment of parasite clearance. Additionally, we searched for all clinical trials or assessments 
of artemisinin combination treatments. We identiﬁ ed 101 references. The only area where 
slow parasite clearance has been unambiguously shown previously is western Cambodia 
(four studies reporting parasite clearance).1,2,22–24 Artemisinin resistance has been suspected 
because of diminishing treatment responses to artemisinin combination therapies on the 
western border of Thailand16,25 and changes in parasite clearance rates on the Kenyan coast.26
Interpretation
Although artemisinin resistance has been suspected outside western Cambodia, this study 
provides the ﬁ rst unequivocal proof that resistance has emerged or spread westward. It 
conﬁ rms (with a large sample size) ﬁ ndings showing that this phenotype is explained mainly 
by a heritable genetic trait in the parasite population. The research suggests a potential 
transmission advantage associated with resistance to artesunate through increased 
gametocyte carriage on admission. These ﬁ ndings suggest that regional artemisinin 
resistance-containment strategies should be reviewed. Increasing the availability of 
artemisinin combination therapies in southeast Asia will reduce the incidence of malaria but 
provides a selection pressure driving artemisinin resistance. The development of strategies 
to reduce the selection and spread of artemisinin-resistant Plasmodium falciparum while 
continuing to drive down the incidence of malaria is of the highest priority.
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elsewhere?7 Genetically determined resistance to artemi-
sinins is now prevalent on the Thailand–Myanmar border, 
contiguous with a malaria endemic area in which a large 
burden of uncontrolled disease exists, so containment 
eﬀ orts will need to be expanded and surveillance and 
control strategies re-examined. Whether the ﬁ tness and 
transmissibility of the resistant parasites in the two 
locations are similar cannot be established yet, and thus 
elimination of falciparum malaria in western Cambodia 
might still be beneﬁ cial through prevention of the spread 
of higher degrees of resistance.
Identiﬁ cation of a molecular marker will be crucial to 
monitor the distribution and spread of resistance and to 
understand the evolution of this trait and the mechanism 
of action of artemisinin. The large numbers of patients 
infected with malaria, high heritability, and the broad 
range of parasite clearance half-lives make the Thailand–
Myanmar border region ideal for powerful association 
studies.32 Clinical studies are needed urgently to map 
further spread and to establish the eﬀ ect of diﬀ erent 
degrees of artemisinin resistance on treatment eﬀ ective-
ness and transmissibility.
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